Research news in clinical context

Immunogenicity following CoronaVac vaccination among people living with HIV is strong but reduced among those with low CD4 counts Evidence on the safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with HIV remains limited. This Brazilian cohort study followed 215 people living with HIV (89% with viral load <50 copies/mL, 70% with CD4 cell count ≥500 cells/mm3) and 296 people with no known immunosuppression who were given two CoronaVac doses 28 days apart. Six weeks after the second vaccine dose, people living with HIV had good overall antibody responses, although compared with people with no known immunosuppression they showed reduced SARS-CoV IgG seroconversion (91% vs 97%) and neutralising antibody (NAb) positivity (71% vs 84%). A CD4 count <500 c/mm3 was associated with lower NAb activity. No serious adverse events were reported. Booster doses or vaccine preparations with higher antigen titres may improve CoronaVac immunogenicity among people with HIV and...

Source: Sexually Transmitted Infections - August 22, 2022 Category: Sexual Medicine Authors: Rusconi, S., Solomon, D., Raffe, S., Daskalopoulou, M. Tags: Perspectives Source Type: research